Newswise — The Cinderella story eventually has a happy ending, but to revelers in the Dimebon story right now the time must feel like five past midnight. Some scientists have considered the sudden transformation of a modest hay fever medicine from Russia into the latest star in the AD drug development arena as a bit of a fairy tale all along. But it was hard for scientists and the media not to get swept up in the excitement over a young biotech company's $725 M dollar deal to develop Dimebon for a heart-breaking disease that has yet to see a truly effective treatment. This week, however, the magic went 'poof' when the first phase 3 in Dimebon's development yielded no significant signal on any measure.
Dimebon Disappoints in Phase 3 Trialhttp://www.alzforum.org/new/detail.asp?id=2387
To trace the rise and fall of this drug, read past Alzforum coverage:
Dimebon for HD—A Hint of Cognitive Benefit?http://www.alzforum.org/new/detail.asp?id=2361
Dimebon: Bright Star or Black Hole?http://www.alzforum.org/new/detail.asp?id=2257
Aβ and Mitochondria—When It Reigns, They Porehttp://www.alzforum.org/new/detail.asp?id=1921
Chicago: Dimebon Safe for 18 Monthshttp://www.alzforum.org/new/detail.asp?id=1893
AD Clinical Pipeline: Immunotherapy Woes, Dimebon Boonshttp://www.alzforum.org/new/detail.asp?id=1879
Trial Troika—Immunotherapy Interrupted, Lipitor Lags, Dimebon Delivershttp://www.alzforum.org/new/detail.asp?id=1807
Washington: Alzhemed Non-story Yields Spotlight to Phase 2 Treatmentshttp://www.alzforum.org/new/detail.asp?id=1606
Boston: Clinical Trial Results for Dimebon Unveiledhttp://www.alzforum.org/new/detail.asp?id=1590
The Alzheimer Research Forum (www.alzforum.org), founded in 1996, is the web's most dynamic scientific community dedicated to understanding Alzheimer disease and related disorders. Access to the web site is free to all. The Forum’s editorial priorities are as diverse as the needs of the research community. The web site reports on the latest scientific findings, from basic research to clinical trials; creates and maintains public databases of essential research data and reagents; and produces discussion forums to promote debate, speed the dissemination of new ideas, and break down barriers across the numerous disciplines that can contribute to the global effort to cure Alzheimer's disease.
The ARF team of professional science writers and editors, information technology experts, web developers and producers all work closely with its distinguished and diverse Advisory Board to ensure a high quality of information and services. The Alzheimer Research Forum is an independent nonprofit organization supported by grants and individual donations. The web site does not endorse any specific product or scientific approach.
RSS